Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 2,413 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Occlusive Vascular Disease Clear all
Terminated Phase 4 Interventional

Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study

NCT00343395
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AVANDAMET
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Mar 17, 2011 · Synced Oct 15, 2026, 10:04 AM EDT
Withdrawn Not applicable Interventional

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

NCT04684212
View directory record Official record
Conditions
Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
Interventions
LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
Device · Drug
Lead sponsor
Brian O'Neill MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Phase 4 Interventional

Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)

NCT00963781
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Thrombosis
Interventions
Medtronic Endeavor Stent, Reduced duration (6 months) DAPT
Device · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 15, 2026, 10:04 AM EDT
Completed No phase listed Observational

Radiographic Imaging Validation and EvALuation for Angio iFR (ReVEAL iFR)

NCT03857503
View directory record Official record
Conditions
Cardiac Ischemia, Coronary Artery Disease, Coronary Stenosis
Interventions
iFR
Diagnostic Test
Lead sponsor
Volcano Corporation
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
19
States / cities
Long Beach, California • Lakewood, Colorado • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

SPIRIT PRIME Clinical Trial

NCT00916370
View directory record Official record
Conditions
Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Core size Xience Prime, Xience Prime Long Lesion (LL)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
56
States / cities
Fairhope, Alabama • Scottsdale, Arizona • Sacramento, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 15, 2026, 10:04 AM EDT
Completed No phase listed Observational Results available

Sundt™ Carotid Shunt Retrospective Post Market Clinical Follow-up Study (PMCF)

NCT03816202
View directory record Official record
Conditions
Carotid Artery Stenosis
Interventions
Sundt carotid shunt
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Newburgh, Indiana • Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Not applicable Interventional Results available

A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)

NCT05358353
View directory record Official record
Conditions
Peripheral Arterial Disease, Critical Limb Ischemia
Interventions
Bare Temporary Spur Stent System
Device
Lead sponsor
ReFlow Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
48
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Orange, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Phase 4 Interventional

TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program

NCT00569751
View directory record Official record
Conditions
Cardiovascular Disease, de Novo Coronary Lesions
Interventions
TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
5,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
53
States / cities
Scottsdale, Arizona • Bakersfield, California • Rancho Mirage, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2008 · Synced Oct 15, 2026, 10:04 AM EDT
Completed No phase listed Observational

Comparing Blood Loss, RBC Transfusions and Inflammatory Marker Changes Among Methods of CPB

NCT01083914
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 15, 2026, 10:04 AM EDT
Terminated Phase 4 Interventional Results available

Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)

NCT01612884
View directory record Official record
Conditions
Thrombosis, Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Not applicable Interventional

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety

NCT00645918
View directory record Official record
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions
clopidogrel, placebo
Drug
Lead sponsor
Accumetrics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
72
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Not applicable Interventional Results available

Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries

NCT02522884
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Tack Endovascular System
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
36
States / cities
Yuma, Arizona • Little Rock, Arkansas • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 15, 2026, 10:04 AM EDT
Terminated No phase listed Observational

LipiScan- Ultrasound INterrogation of Atherosclerotic Coronary Arteries:

NCT02953613
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis
Interventions
NIRS/IVUS
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 15, 2026, 10:04 AM EDT
Recruiting Not applicable Interventional

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma

NCT07704918
View directory record Official record
Conditions
Melanoma
Interventions
Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 15, 2026, 10:04 AM EDT
Terminated No phase listed Observational

Incidence of Male Pudendal Artery Stenosis in Suboptimal Erections Study

NCT01341483
View directory record Official record
Conditions
Erectile Dysfunction Due to Arterial Insufficiency
Interventions
Not listed
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
35 Years to 70 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 15, 2026, 10:04 AM EDT
No Longer Available No phase listed Expanded access

Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver

NCT00143546
View directory record Official record
Conditions
Hepatic Veno-occlusive Disease
Interventions
Defibrotide
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Not applicable Interventional Results available

Absorb IV Randomized Controlled Trial

NCT02173379
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
98
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 15, 2026, 10:04 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Immunomodulatory Effects of PCSK9 Inhibition

NCT05720156
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases, Atherosclerosis, Arterial Inflammation, Vascular Diseases, Vascular Disease, Peripheral, Vascular Calcification, High Cholesterol/Hyperlipidemia, Heart Diseases, Heart Attack, Stroke, Cerebrovascular Accident, Carotid Artery Diseases, Carotid Atherosclerosis, Transient Ischemic Attack
Interventions
99mTc-tilmanocept SPECT/CT scanning
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Not applicable Interventional

Effects of Almonds On Endothelial Function In Patients With Coronary Artery Disease

NCT01038362
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
NCEP Step 1 diet plus Almonds, No Almonds
Other
Lead sponsor
Boston University
Other
Eligibility
21 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 23, 2009 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

NCT03001297
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, MEDI5884 Dose 1, MEDI5884 Dose 2, MEDI5884 Dose 3, MEDI5884 Dose 4
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Phase 2 Interventional

An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks

NCT00695305
View directory record Official record
Conditions
Atherosclerosis
Interventions
rilapladib, placebo, 18F Fluorodeoxylucose (FDG)-PET
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Boston, Massachusetts • Brockton, Massachusetts • Haverhill, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 15, 2026, 10:04 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity

NCT00326690
View directory record Official record
Conditions
Congestive Heart Failure, Ischemic Cardiomyopathy, Coronary Artery Disease, Myocardial Diseases
Interventions
Blue Egg Device
Device
Lead sponsor
BioVentrix
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
9
States / cities
Los Angeles, California • St. Petersburg, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 15, 2026, 10:04 AM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
204
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 15, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

NCT01000727
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Darapladib 160 mg, Placebo, Standard Therapy
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
13,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
290
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 252 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 15, 2026, 10:04 AM EDT